6Poser CM, Paty DW, Schernbery L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols[J]. Ann Neural, 1983,13(3) :227 - 231.
7Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute rehpse in MS[J]. Neurology, 1989, 39 : 369.
8Lyous PR, Nevman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: A profile of adverse effects[J] .J Neuro Neurosurg Psychiat, 1988,51:285.
5[4] Poser CM , Paly UM, Scheinbre L. New diagnostic criteria for multiple sclerosis guidelines for research protocols[J]. Ann Neurol, 1983,13:227-231.
6[5] Yagi Y, Takahashi M, Nakamura Y. Cytokine-secreting cells in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone[J]. Rinsho Shinkeigaku, 1997,37(7):575-579.
7[6] Gelati M, Corsini E, Dufour A, et al. Reduced adhesion of PBMNCs to endothelium in methylprednisolone-treated MS patients: preliminary results[J]. Acta Neurol Scand, 1997,96(5):283-392.
8[7] De Waat-Malefyt R, Haanen J, Spits H,et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class Ⅱ major histocompatibility complexes expression[J]. J Exp Med, 1991,174:915-924.
9[9] Gayo A, Mozo L, Sulez A, et al. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse[J]. J Neuroimmunol, 1998,85:122-30.
